TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04807634

Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous Lipid Emulsion (Intralipid 20%)
Description: Lipid emulsion or fat emulsion refers to an emulsion of lipid for human intravenous use. It is often referred to by the brand name of the most commonly used version, Intralipid, which is an emulsion of soy bean oil, egg phospholipids and glycerin, and is available in 10%, 20% and 30% concentrations. The 30% concentration is not approved for direct intravenous infusion, but should be mixed with amino acids and dextrose as part of a total nutrient admixture.

Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous Lipid Emulsion (Intralipid 20%)
Description: Lipid emulsion or fat emulsion refers to an emulsion of lipid for human intravenous use. It is often referred to by the brand name of the most commonly used version, Intralipid, which is an emulsion of soy bean oil, egg phospholipids and glycerin, and is available in 10%, 20% and 30% concentrations. The 30% concentration is not approved for direct intravenous infusion, but should be mixed with amino acids and dextrose as part of a total nutrient admixture.
Study: NCT05089396

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maxillary protraction
Description: A petit facemask will be used for maxillary protraction along with a facemask splint (two acrylic bite blocks connected through a transpalatal arch) in the active comparator group. in the experimental group, two miniscrews will be inserted in the anterior region of the palate one on each side of the midline to provide skeletal anchorage for the facemask splint. in both groups, a force of 380 gm to 400 gm will be applied through the extra-oral elastics the will be attached to the facemask on one side and to the facemask splint on the other side.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maxillary protraction
Description: A petit facemask will be used for maxillary protraction along with a facemask splint (two acrylic bite blocks connected through a transpalatal arch) in the active comparator group. in the experimental group, two miniscrews will be inserted in the anterior region of the palate one on each side of the midline to provide skeletal anchorage for the facemask splint. in both groups, a force of 380 gm to 400 gm will be applied through the extra-oral elastics the will be attached to the facemask on one side and to the facemask splint on the other side.
Study: NCT05840653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychotherapeutic intervention
Description: The group that will receive 5-week positive psychotherapy-based hope placement psychoeducation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psychotherapeutic intervention
Description: The group that will receive 5-week positive psychotherapy-based hope placement psychoeducation
Study: NCT05684887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital based contact tracing
Description: * Listing of contacts by SARS-CoV-2 positive individuals in Mamal Pro app + verification and validation by a health care worker.~* Immediate access to the contact list in Mamal Pro once validated by the health care worker.~* Contacts are immediately notified by text message automatically sent to all contacts with phone numbers and later called by the HCWs responsible for carrying out the contact tracing at the district level.~* Contacts will be invited to go to the nearest testing facilities/units to get tested.~* Those who are unable or refuse to come for testing are followed up by phone for 10 days for the occurrence of COVID-19 symptoms.~* Information about the contact tracing process during communication with contacts are recorded in Mamal Pro digital contact tracing module.
Study: NCT06505785

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The creative drama group
Description: 10 weeks, once a week, each session will last approximately 2 hours and will be facilitated by a trained instructor in creative drama.~Sessions will include role-playing, improvisation, and scenario-based activities focusing on midwifery care situations, communication with patients, and empathy development.
Study: NCT04911127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200mg Cannabidiol by capsules twice daily
Description: 200mg twice daily via 50mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 400mg Cannabidiol by capsules twice daily
Description: 400mg twice daily via 50mg capsules
Study: NCT06263777

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurses training program on early detection of disability
Description: It included four main elements, which are: a booklet defining different disabilities, a list of the guidelines for early detection, a guide for family guidance for families of children with disabilities, a monitoring and follow-up form for 8 cases of children with disabilities). The program consisted of twelve training sessions with a total of 48 hours (4 hours per session) and was based on the techniques of lecture, dialogue, working groups, cooperative learning techniques and participatory learning
Study: NCT04911127

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: MCT oil capsules as placebo for CBD
Study: NCT05243602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Switch to B/F/TAF
Description: This is a combined pill containing 50mg of bictegravir, 200mg of emtricitabine and 25mg of tenofovir alafenamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continue current regimen
Description: Participants will continue taking the same ARV regimen they were on before enrollment with no change in drug or dosage for the duration of the trial
Study: NCT06147440

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Participants receive diets following different dietary patterns for 1 week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Participants receive diets following different dietary patterns for 1 week.
Study: NCT05315986

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saffr'Inside; 30mg
Description: Ingestion of one gummy sweet of Saffr'Inside; 30mg, on a daily basis for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Saffr'Inside; 30mg
Description: Ingestion of one gummy sweet of Saffr'Inside; 30mg, on a daily basis for 4 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Sleep Education
Description: Psycho-education based multi-component sleep intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Sleep Education
Description: Psycho-education based multi-component sleep intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo food supplement
Description: Placebo food supplement identical to the active gummy sweet of Saffr'Inside; 30mg, on a daily basis for 4 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo food supplement
Description: Placebo food supplement identical to the active gummy sweet of Saffr'Inside; 30mg, on a daily basis for 4 weeks.
Study: NCT04640909

Intervention type: OTHER
Group type: OTHER
Intervention: Peripheral blood samples withdrawal
Description: Peripheral blood samples evaluation
Study: NCT06540482

Intervention type: DIAGNOSTIC_TEST
Intervention: Reliability test
Description: The test was administered two days apart to evaluate the reliability of the retest test.
Study: NCT04629300

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Care Mobile Application
Description: Tablet computer with application providing modules on skills for managing symptoms and coping.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Standard oncology care with monitoring of supportive care services usage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Standard oncology care with monitoring of supportive care services usage
Study: NCT05567588

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Drug: Pembrolizumab
Description: 200mg(body weight \>75kg) or 100mg(body weight≤75kg) given intravenously over 30 minutes day 1 of every 3 week cycle until progression as per immune related response criteria.
Study: NCT06114017

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Media Abstention
Description: People will stop or reduce their social media use for one week.
Study: NCT05309031

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water Immersion
Description: Participants will enter the pool, which has a thermoneutral temperature of 33°C (92°F), warm enough to be comfortable, but cool enough to avoid an increase in HR with similar ambient air temperature. A maximum depth of 4 to 4 feet 6 inches allows ample room participants to be immersed to the chest, float vertically and move in the pool. During 45 min of immersion, they will be instructed to stand, walk and move ad lib. Noodles will be available to hang or rest on in a vertical position. Taller participants will remain at the pool's deep end. The timeframe was chosen to approximate our previous immersion intervention length.
Study: NCT05683496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lonigutamab
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lonigutamab
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lonigutamab
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lonigutamab
Description: subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: subcutaneous injection
Study: NCT06543511

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Blood Test
Description: Germline genetic testing using skin fibroblasts
Study: NCT04989231

Intervention type: BIOLOGICAL
Intervention: Investigational sIPV
Description: Three intramuscular injections of the investigational vaccine (0.5 ml) at 0 month ,1 month and 2 months respectively; Single intramuscular injection of the investigational vaccine (0.5 ml) at 18 months

Intervention type: BIOLOGICAL
Intervention: Control IPV
Description: Three intramuscular injections of the control vaccine (0.5 ml) at 0 month ,1 month and 2 months respectively;Single intramuscular injection of the control vaccine (0.5ml) at 18 months
Study: NCT05092451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR.70/IL15-transduced CB-NK cells
Description: Given by IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: Given by IV
Study: NCT04395456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMY-101
Description: C3 complement inhibitor

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: WFI 5% glucose
Description: Placebo
Study: NCT06078124

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sibling Support for Adolescent Girls in Emergencies
Description: The Sibling Support for Adolescent Girls in Emergencies (SSAGE) intervention is a gender-transformative, 12-week program utilizing a whole family approach wherein an adolescent girl, her male sibling, and a male and female caregiver participate in sessions that are age- and gender-specific and combined with family-wide discussions of session learnings. The sessions are interactive, engaging, and promote self-reflection and discussion on topics such as power, gender, interpersonal communication, and healthy relationships. Given the whole-family approach, SSAGE addresses intersections between spousal relationships, caregiver-child relationships, and relationships between siblings, as they pertain to supporting the mental health and psychosocial well-being of adolescent girls.
Study: NCT05871814

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colon preparation guided by an artificial intelligence device
Description: Regular oral and written information will be provided to this group. In addition, participants will take a picture of the last rectal effluent with the smart phone that have to upload to a server. A convolutional neural network will assess whether the bowel preparation is correct or not (clean or not). The system will issue specific recommendations based on the quality of cleansing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Colon preparation guided by an artificial intelligence device
Description: Regular oral and written information will be provided to this group. In addition, participants will take a picture of the last rectal effluent with the smart phone that have to upload to a server. A convolutional neural network will assess whether the bowel preparation is correct or not (clean or not). The system will issue specific recommendations based on the quality of cleansing
Study: NCT06451757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonlicromanol
Description: Oral administration of 100 mg sonlicromanol (KH176) twice daily during 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration of 100 mg placebo twice daily during 52 weeks
Study: NCT06497907

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: polymeric formula
Description: Patients with growth faltering received nutritional rehabilitation with polymeric formula and were reassessed after 12 weeks by anthropometric measurements

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: peptide based formula
Description: patients who were defined as non responders and underwent upper gastrointestinal endoscopy and diagnosed as environmental enteropathy, received nutritional rehabilitation with peptide based formula
Study: NCT05651594

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scans

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Perceived Stress Scale
Study: NCT06225791

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MMS (90x2) + BCC or expanded BCC
Description: Provision of 90-count bottles x 2, with enhanced MMS delivery strategy (5 districts with MMS orientation with BCC; 8 districts with MMS orientation with expanded BCC)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MMS (180x1) + BCC or expanded BCC
Description: Provision of 180-count bottles x 1, with enhanced MMS delivery strategy (5 districts with MMS orientation with BCC; 8 districts with MMS orientation with expanded BCC)
Study: NCT06181773

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EPO Feeding Program
Description: The EPO Feeding program focused on providing parents with information based on scientific evidence and the most current nutritional recommendations regarding positive feeding practices and healthy eating during the preschool years.
Study: NCT05092451

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: Given by IV
Study: NCT05860608

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Us2.ai (AI-enabled report) handheld echocardiogram
Description: NT-proBNP will be performed in all individuals randomized to the ACTIVE arm at the same visit as informed consent, and those with elevated NT-proBNP (≥125pg/ml) will be invited to attend a visit for an Us2.ai (AI-enabled) echocardiogram which will be controlled with a standard echocardiographic study if the AI-echo is non-diagnostic.

Intervention type: DEVICE
Group type: OTHER
Intervention: Us2.ai (AI-enabled report) handheld echocardiogram
Description: NT-proBNP will be performed in all individuals randomized to the ACTIVE arm at the same visit as informed consent, and those with elevated NT-proBNP (≥125pg/ml) will be invited to attend a visit for an Us2.ai (AI-enabled) echocardiogram which will be controlled with a standard echocardiographic study if the AI-echo is non-diagnostic.
Study: NCT04815356

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD22CART cell infusion
Description: The treatment regimen will consist of lymphodepleting chemotherapy followed by CD22CART infusion: Days -4 to -2: fludarabine 25 mg/m2/dose Day -2: cyclophosphamide 900 mg/m2/dose Day 0: CD22CART infusion (starting at dose level 1 \[DL1\]: 1 x 105 transduced CAR-T cells/kg) on Day 0 Subjects will be evaluated for response at Day 28 post-CD22CART infusion.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD22CART cell infusion
Description: The treatment regimen will consist of lymphodepleting chemotherapy followed by CD22CART infusion: Days -4 to -2: fludarabine 25 mg/m2/dose Day -2: cyclophosphamide 900 mg/m2/dose Day 0: CD22CART infusion (starting at dose level 1 \[DL1\]: 1 x 105 transduced CAR-T cells/kg) on Day 0 Subjects will be evaluated for response at Day 28 post-CD22CART infusion.
Study: NCT05785754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCSZ11
Description: A monoclonal antibody that binds to CD93, DCSZ11 will be administered as a single intravenous (IV) infusion on Day 1 in each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCSZ11
Description: A monoclonal antibody that binds to CD93, DCSZ11 will be administered as a single intravenous (IV) infusion on Day 1 in each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DCSZ11
Description: A monoclonal antibody that binds to CD93, DCSZ11 will be administered as a single intravenous (IV) infusion on Day 1 in each 21-day cycle.
Study: NCT06116773

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Training group is supervised exercise group and will be included in a supervised cardiac rehabilitation program for 3 days a week. The program will start 2 weeks after CABG surgery and continue for 8 weeks, totaling 24 sessions. Aerobic, resistance, balance and stretching exercises will be applied within the program. Total exercise time is aimed to be ≥150 min/week for 8 weeks. A home-based exercise program will be recommended.~Moderate-intensity continuous aerobic training will be implemented using an upright exercise bike (5 minutes warm-up, 20 minutes load, 5 minutes cool down, 5 minutes recovery). Rhythmic unloaded aerobic exercises or low-load (0.5-1 kg) resistance exercises (starting from the 6th week post-op) will be performed for an average of 15-20 minutes. Balance exercises will progress from easy to difficult depending on the person's performance. Stretching exercise for the gastrocnemius muscle will be performed for 4 repetitions in a short stretching period of 15 seconds.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Patients will be informed about secondary prevention approaches which is routinely performed after discharge after CABG operation and will be recommended a home-based exercise program. Patients will be called by phone once a week and exercise monitoring will be provided. Recommended home exercise program includes:~* Breathing exercises~* Moderate intensity (RPE 4-6) walking (150 min/week).~* Posture exercises (shoulder elevation-depression, 90 degree shoulder flex-extend, 90 degree shoulder abd-add, neck joint range of motion exercises)~* They will be advised to continue range of motion exercises in the early post-operative period. (Twice a day, 10 repetitions).These exercises include ankle dorsi-plantar flexion, hip abduction-adduction, hip internal-external rotation, hip flexion-extension, arm elevation-depression in the supine position; flexion-extension in the sitting position; hip abduction-adduction, hip hyperextension and counting movements in the standing position.
Study: NCT05487924

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SVV-GDHT
Description: GDHT guided by SVV using Flotra/Vigileo monitor

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: O2ER-GDHT
Description: GDHT guided by O2ER

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional care
Description: conventional fluid therapy without GDHT
Study: NCT05148000

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: QM1114-DP
Description: QM1114-DP
Study: NCT05075317

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard cardiac rehabilitation
Description: Standard, multi-dimensional cardiac rehabilitation program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard cardiac rehabilitation
Description: Standard, multi-dimensional cardiac rehabilitation program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-Restricted Eating
Description: Counselling to restrict their eating to between 11 am and 7 pm and to consume water-only for the remaining 16 hours per day
Study: NCT05785754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab injection
Study: NCT05836038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visio-Tactile Stimulation
Description: They will see their virtual hand touched while simultaneously feel their opposite real hand touched in the same pattern.
Study: NCT05947539

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kisoboka Mukwano (It is possible, my love!) Intervention
Description: The intervention consists of 5 bi-weekly sessions each lasting 60 to 90 minutes. It uses motivational interviewing, peer navigation, and behavioral economics to promote strategies for economic strengthening, reductions in male partner alcohol use, coping with relationship conflict and stress, changing norms that reduce intimate partner violence and support engagement in HIV care and antiretroviral therapy (ART) adherence among adolescent girls and young women living with HIV, and, thereby, enhances future sustained viral suppression and benefits of treatment as prevention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Screening and Referral
Description: Intimate partner violence screening, alcohol screening, and referral
Study: NCT06573632

Intervention type: DIETARY_SUPPLEMENT
Intervention: TPN-N7 Baxter
Description: providing TPN to all malnutrition patients preoperatively as well as postoperatively.